SCHEMBL25319978

SCHEMBL25319978

CCCCCCCCCCN(CCCCCCCCCC)C(=O)CCCCCCCN(CCCN)CCCCCCCC(=O)N(CCCCCCCCCC)CCCCCCCCCC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 6/20 0.53
KDM4C Q9H3R0 4/20 0.53
PHF8 Q9UPP1 3/20 0.53
CA12 O43570 2/20 0.49
CA1 P00915 2/20 0.49
CA2 P00918 2/20 0.49
CA4 P22748 2/20 0.49
ACHE P22303 1/20 0.43
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
EPHX2 P34913 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25321572 1.00 KDM5A (0.53) KDM5AKDM4CPHF8CA12CA1
SCHEMBL18502175 0.93 ACHE (0.48) KDM5AKDM4CPHF8CA12CA1
SCHEMBL17645573 0.93 CES2 (0.45) CA12CA1CA2CA4ACHE
SCHEMBL6156406 0.93 CES2 (0.45) CA12CA1CA2CA4ACHE
SCHEMBL28424085 0.91 ACHE (0.49) KDM5AKDM4CPHF8ACHEHDAC3
SCHEMBL17424013 0.91 ACHE (0.46) KDM5AKDM4CPHF8CA12CA1
Hydrochloric Acid SCHEMBL19924856 0.91 DNM1 (0.46) CA12CA1CA2CA4ACHE
Hydrochloric Acid SCHEMBL19924864 0.91 DNM1 (0.46) CA12CA1CA2CA4ACHE
SCHEMBL25318457 0.91 KDM5A (0.60) KDM5AKDM4CPHF8CA12CA1
SCHEMBL25414991 0.91 KDM5A (0.60) KDM5AKDM4CPHF8CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188020-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS ACUITAS THERAPEUTICS INC (CA) 2025-06-12 US disclosed
US-12129223-B2 Lipids for use in lipid nanoparticle formulations Acuitas Therapeutics, Inc. (CA) 2024-10-29 US disclosed
EP-4448485-A2 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2024-10-23 EP disclosed
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-09-21 US disclosed
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-09-21 US disclosed
WO-2023114943-A2 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-06-22 WO disclosed
WO-2023114943-A2 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS PHOSPHO1, SGMS1, NPC1 KDM5A 4843/4885KDM4C 4318/4885PHF8 4286/4885
US-20250188020-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS PHOSPHO1, SGMS1, NPC1 KDM5A 4843/4885KDM4C 4318/4885PHF8 4286/4885
US-12129223-B2 Lipids for use in lipid nanoparticle formulations PHOSPHO1, SGMS1, NPC1 KDM5A 4843/4885KDM4C 4318/4885PHF8 4286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.